Physician profile
Keith Watts
NPI 1710432190
$13,193.84
in general payments reported to CMS, 2019-2025
35 companies · $2,845 in 2025
The $2,845 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,859 · 2022: $2,045 · 2023: $2,945 · 2024: $3,499 · 2025: $2,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,275 · Education: $14.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,275.29 |
| Education | $14.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,879.53 | 2021-2025 | |
| Alkermes, INC. | $1,867.30 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,313.59 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $807.54 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $764.20 | 2021-2025 | Spravato |
| Corium, LLC | $761.91 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $749.72 | 2021-2025 | Ingrezza |
| Bausch Health US, LLC | $704.26 | 2021-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $647.13 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $494.80 | 2022-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $420.49 | 2021-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $408.55 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Lundbeck LLC | $399.51 | 2021-2024 | Rexulti |
| Indivior INC. | $384.75 | 2021-2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $227.57 | 2021-2025 | Qelbree, Qelbree |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $174.73 | 2022-2024 | Adzenys Xr-Odt |
| Harmony Biosciences LLC | $173.39 | 2023-2024 | Wakix |
| Teva Pharmaceuticals USA, INC. | $154.69 | 2024-2025 | Austedo Xr, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $135.82 | 2021-2024 | |
| Tris Pharma INC | $113.37 | 2022-2025 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $96.51 | 2021 | |
| Idorsia Pharmaceuticals US INC | $94.55 | 2022-2024 | Quviviq |
| Jazz Pharmaceuticals INC. | $85.50 | 2021-2022 | |
| Eisai INC. | $51.53 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.33 | 2025 | Cobenfy |
| Biohaven Pharmaceutical Holding Company LTD. | $45.37 | 2022 | |
| Avanir Pharmaceuticals, INC. | $44.45 | 2021 | |
| Braeburn INC. | $23.81 | 2025 | Brixadi |
| Avion Pharmaceuticals | $21.68 | 2023 | Methylphenidate Hydrochloride |
| Vertical Pharmaceuticals, LLC | $21.16 | 2024 | Relexxii |
| Sage Therapeutics, LLC | $18.71 | 2024 | |
| Orexo US, INC. | $16.30 | 2022 | |
| Collegium Pharmaceutical, INC. | $15.49 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $14.02 | 2021 | |
| Adlon Therapeutics L.P. | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.